Literature DB >> 3257783

Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled.

R W Steketee1, S G Wassilak, W N Adkins, D G Burstyn, C R Manclark, J Berg, D Hopfensperger, W L Schell, J P Davis.   

Abstract

During an outbreak of pertussis in residents and staff of a facility for the developmentally disabled, 149 persons had laboratory evidence of Bordetella pertussis infection; 130 (87%) reported respiratory illness. Infection rates (IR) in affected wards ranged from 6% to 91%. Most residents were adolescents and adults and had received a full course of diphtheria-tetanus toxoids-pertussis (DTP) vaccine; IRs increased with increasing time after the last DTP dose in fully vaccinated residents. The IR was lower in residents on wards where erythromycin treatment/prophylaxis was started two or fewer weeks after the onset of illness in the first case on the ward (IR, 16%), compared with four or more weeks after onset (IR, 75%; P less than 10(-6)). Respiratory symptoms were milder in ill residents treated within seven days of onset of illness. Although B. pertussis transmission was substantial, erythromycin treatment of patients and prophylaxis of exposed persons was effective in decreasing transmission and disease severity. Carbamazepine toxicity occurred in seven (19%) of 37 residents when carbamazepine was administered with erythromycin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257783     DOI: 10.1093/infdis/157.3.434

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Management of people exposed to pertussis and control of pertussis outbreaks.

Authors: 
Journal:  CMAJ       Date:  1990-10-15       Impact factor: 8.262

2.  Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).

Authors:  Jennifer L Liang; Tejpratap Tiwari; Pedro Moro; Nancy E Messonnier; Arthur Reingold; Mark Sawyer; Thomas A Clark
Journal:  MMWR Recomm Rep       Date:  2018-04-27

3.  A comparison of 2 strategies to prevent infection following pertussis exposure in vaccinated healthcare personnel.

Authors:  William P Goins; Kathryn M Edwards; Cindy L Vnencak-Jones; Michael T Rock; Melanie Swift; Valerie Thayer; William Schaffner; Thomas R Talbot
Journal:  Clin Infect Dis       Date:  2012-01-11       Impact factor: 9.079

Review 4.  Metabolism and excretion of mood stabilizers and new anticonvulsants.

Authors:  T A Ketter; M A Frye; G Corá-Locatelli; T A Kimbrell; R M Post
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

5.  Protective role of immunoglobulin G antibodies to filamentous hemagglutinin and pertactin of Bordetella pertussis in Bordetella parapertussis infection.

Authors:  Q He; K Edelman; H Arvilommi; J Mertsola
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-10       Impact factor: 3.267

6.  Factors influencing the spread of pertussis in households.

Authors:  C H Wirsing von König; S Postels-Multani; H Bogaerts; H L Bock; S Laukamp; S Kiederle; H J Schmitt
Journal:  Eur J Pediatr       Date:  1998-05       Impact factor: 3.183

7.  Seroprevalence of pertussis antibody among health care personnel in Spain.

Authors:  Jose-Ramón de Juanes; Angel Gil; Antonio González; María-Pilar Arrazola; María San-Martín; Jesús Esteban
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

8.  Tetanus, diphtheria and acellular pertussis (Tdap) vaccination among healthcare personnel-United States, 2011.

Authors:  Peng-jun Lu; Samuel B Graitcer; Alissa O'Halloran; Jennifer L Liang
Journal:  Vaccine       Date:  2013-12-03       Impact factor: 3.641

9.  Symptoms and complications of pertussis in adults.

Authors:  S Postels-Multani; H J Schmitt; C H Wirsing von König; H L Bock; H Bogaerts
Journal:  Infection       Date:  1995 May-Jun       Impact factor: 3.553

10.  Pertussis post-exposure prophylaxis among household contacts: a cost-utility analysis.

Authors:  Nisha Thampi; Ipek Gurol-Urganci; Natasha S Crowcroft; Beate Sander
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.